Technical Analysis for QURE - uniQure N.V.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 6.79 | -1.59% | -0.11 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | 0.00% | |
| New 52 Week Low | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | -1.59% | |
| Slingshot Bearish | Bearish Swing Setup | -2.02% | |
| Wide Bands | Range Expansion | -2.02% | |
| Oversold Stochastic | Weakness | -2.02% | |
| New 52 Week Closing Low | Bearish | -0.88% | |
| New 52 Week Low | Weakness | -0.88% | |
| Wide Bands | Range Expansion | -0.88% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakdown | about 12 hours ago |
| Down 3% | about 12 hours ago |
| Down 2 % | about 13 hours ago |
| Fell Below Previous Day's Low | about 13 hours ago |
| New 52 Week Low | about 13 hours ago |
Get a Trading Sidekick!
- Earnings date: 10/31/2023
uniQure N.V. Description
uniQure BV, a biopharmaceutical company, develops gene therapies through its modular technology platform for the treatment of genetic or acquired diseases. The company offers Glybera for the treatment of patients with lipoprotein lipase deficiency, an orphan metabolic disease. It also develops a pipeline of additional adeno-associated virus (AAV) based gene therapies, including AMT-060, a gene therapy for the treatment of hemophilia B; AMT-021 for acute intermittent porphyria; AMT-110 for Sanfilippo B syndrome; and AAV2/glial cell line-derived neurotrophic factor for Parkinson's disease, as well as various programs that are in early preclinical development stage. The company has collaborations with Chiesi Farmaceutici S.p.A., Digna Biotech, Institut Pasteur, and University of California San Francisco. uniQure BV was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Biology Disease Clinical Development Genetics Gene Therapy Parkinson's Disease Metabolic Disease Applied Genetics Gene Delivery Hemophilia Lipoprotein Treatment Of Hemophilia Adeno Associated Virus Acute Intermittent Porphyria Alipogene Tiparvovec Glybera Hemophilia B Lipase Lipoprotein Lipase Deficiency
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 28.255 |
| 52 Week Low | 6.67 |
| Average Volume | 962,607 |
| 200-Day Moving Average | 16.79 |
| 50-Day Moving Average | 8.53 |
| 20-Day Moving Average | 7.58 |
| 10-Day Moving Average | 7.20 |
| Average True Range | 0.39 |
| RSI (14) | 29.08 |
| ADX | 40.98 |
| +DI | 11.60 |
| -DI | 32.00 |
| Chandelier Exit (Long, 3 ATRs) | 7.93 |
| Chandelier Exit (Short, 3 ATRs) | 7.84 |
| Upper Bollinger Bands | 8.65 |
| Lower Bollinger Band | 6.51 |
| Percent B (%b) | 0.13 |
| BandWidth | 28.17 |
| MACD Line | -0.55 |
| MACD Signal Line | -0.54 |
| MACD Histogram | -0.012 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 7.17 | ||||
| Resistance 3 (R3) | 7.17 | 7.04 | 7.10 | ||
| Resistance 2 (R2) | 7.04 | 6.95 | 7.04 | 7.08 | |
| Resistance 1 (R1) | 6.92 | 6.89 | 6.86 | 6.92 | 7.06 |
| Pivot Point | 6.79 | 6.79 | 6.76 | 6.79 | 6.79 |
| Support 1 (S1) | 6.67 | 6.70 | 6.61 | 6.67 | 6.52 |
| Support 2 (S2) | 6.54 | 6.64 | 6.54 | 6.50 | |
| Support 3 (S3) | 6.42 | 6.54 | 6.48 | ||
| Support 4 (S4) | 6.42 |
